QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-25
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, prospective study enrolling 30 patients with stage II-III triple-negative breast cancer. The neoadjuvant regimen consists of QL1706 combined with carboplatin plus albumin-bound paclitaxel (21-day cycles for 4 cycles) followed by QL1706 combined with doxorubicin/epirubicin plus cyclophosphamide (21-day cycles for 4 cycles). The treatment observation period is 1 year, and the primary endpoint is the pathological complete response rate.